Letolizumab
Monoclonal antibody
- none
- 1450981-87-9
- none
- 449MIE2SD6
- D11122
Letolizumab (INN;[1] development code BMS-986004) is a humanized monoclonal antibody designed for the treatment of inflammatory diseases.[2]
This drug was developed by Bristol-Myers Squibb.[3]
References
- ^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 116" (PDF). WHO Drug Information. 30 (4).
- ^ Budamakuntla L, Shree-Lakshmi HV, Bansal A, Venkatarayaraju SK (2019). "Spotlight on itolizumab in the treatment of psoriasis - current perspectives from India". Psoriasis: Targets and Therapy. 9: 19–27. doi:10.2147/PTT.S154073. PMC 6501705. PMID 31119094.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Letolizumab, American Medical Association.
- v
- t
- e
Monoclonal antibodies for the immune system
Human | |
---|---|
Humanized | |
Veterinary |
Mouse |
|
---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
![]() | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e